Neuphoria Therapeutics Inc. (NEUP)

NASDAQ: NEUP · Real-Time Price · USD
4.710
+0.180 (3.97%)
At close: Oct 28, 2025, 4:00 PM EDT
4.750
+0.040 (0.85%)
Pre-market: Oct 29, 2025, 4:13 AM EDT
3.97%
Market Cap11.10M
Revenue (ttm)15.65M
Net Income (ttm)-369,632
Shares Out 2.36M
EPS (ttm)-0.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume883,468
Open4.760
Previous Close4.530
Day's Range4.645 - 5.090
52-Week Range2.900 - 126.000
Betan/a
AnalystsStrong Buy
Price Target28.00 (+494.48%)
Earnings DateNov 15, 2025

About NEUP

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for th... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 8
Stock Exchange NASDAQ
Ticker Symbol NEUP
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for NEUP stock is "Strong Buy." The 12-month stock price target is $28.0, which is an increase of 494.48% from the latest price.

Price Target
$28.0
(494.48% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments f...

1 day ago - GlobeNewsWire

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.

Other symbols: CTXRPCAR
7 days ago - Benzinga

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neupho...

8 days ago - GlobeNewsWire

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025

4 weeks ago - GlobeNewsWire

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments ...

7 weeks ago - GlobeNewsWire

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments f...

2 months ago - GlobeNewsWire

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments fo...

5 months ago - GlobeNewsWire

Neuphoria Provides First Quarter 2025 Business Updates

BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments fo...

5 months ago - GlobeNewsWire

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Initiation by Merck of a Phase 2 trial in Alzheimer's disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company's pipeline diversification beyond BNC210 US $15M milesto...

7 months ago - GlobeNewsWire

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology developing impactful treatments for neuropsy...

8 months ago - GlobeNewsWire

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator Milestone payment tr...

9 months ago - GlobeNewsWire

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangemen...

11 months ago - GlobeNewsWire